BRPI0409711A - tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina - Google Patents

tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina

Info

Publication number
BRPI0409711A
BRPI0409711A BRPI0409711-4A BRPI0409711A BRPI0409711A BR PI0409711 A BRPI0409711 A BR PI0409711A BR PI0409711 A BRPI0409711 A BR PI0409711A BR PI0409711 A BRPI0409711 A BR PI0409711A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
viral respiratory
respiratory infections
alpha thymosin
Prior art date
Application number
BRPI0409711-4A
Other languages
English (en)
Inventor
Alfred R Rudolph
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of BRPI0409711A publication Critical patent/BRPI0409711A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"TRATAMENTO OU PREVENçãO DE INFECçõES RESPIRATóRIAS VIRAIS COM PEPTìDEOS DA ALFA TIMOSINA". Um peptídeo da alfa timosina é administrado em um paciente que tenha contraído, ou esteja com risco de contrair uma infecção respiratória viral, uma infecção por coronavírus e/ou SARS.
BRPI0409711-4A 2003-04-23 2004-04-23 tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina BRPI0409711A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46464503P 2003-04-23 2003-04-23
US47042003P 2003-05-15 2003-05-15
PCT/US2004/012663 WO2004094991A2 (en) 2003-04-23 2004-04-23 Treatment or prevention of respiratory viral infections with alpha thymosin peptides

Publications (1)

Publication Number Publication Date
BRPI0409711A true BRPI0409711A (pt) 2006-05-02

Family

ID=33313489

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409711-4A BRPI0409711A (pt) 2003-04-23 2004-04-23 tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina

Country Status (12)

Country Link
US (1) US20070036744A1 (pt)
EP (1) EP1635854A4 (pt)
JP (1) JP2006524704A (pt)
KR (1) KR20060013515A (pt)
AU (1) AU2004232847B2 (pt)
BR (1) BRPI0409711A (pt)
CA (1) CA2522891A1 (pt)
EA (1) EA009945B1 (pt)
MX (1) MXPA05011304A (pt)
NO (1) NO20055512L (pt)
NZ (1) NZ543651A (pt)
WO (1) WO2004094991A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
RS52377B (sr) * 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
WO2010033240A2 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
WO2010033227A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
CN111671886B (zh) * 2020-03-05 2022-11-15 上海甘翼生物医药科技有限公司 一种预防高危易感人群感染冠状病毒或发生冠状病毒感染疾病的药物组合及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3100974A1 (de) * 1980-01-18 1982-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente enthaltende arzneimittel mit immunregulierender wirkung, und thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-fragmente
US4612365A (en) * 1980-03-25 1986-09-16 Max-Planck-Gesellschaft Zur Foederung Der Wissenschaften Medicaments containing alpha 1-thymosin and having an immuno regulatory action and alpha 1-thymosin fragments
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy

Also Published As

Publication number Publication date
NZ543651A (en) 2007-01-26
WO2004094991A2 (en) 2004-11-04
MXPA05011304A (es) 2005-12-12
EP1635854A4 (en) 2009-08-12
WO2004094991A3 (en) 2004-12-16
NO20055512L (no) 2005-11-22
US20070036744A1 (en) 2007-02-15
EP1635854A2 (en) 2006-03-22
JP2006524704A (ja) 2006-11-02
CA2522891A1 (en) 2004-11-04
AU2004232847B2 (en) 2008-11-20
EA200501569A1 (ru) 2006-06-30
AU2004232847A1 (en) 2004-11-04
EA009945B1 (ru) 2008-04-28
KR20060013515A (ko) 2006-02-10

Similar Documents

Publication Publication Date Title
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
BR0010593A (pt) Terapia de combinação com antagonista de ccr5-interferon alfa peguilado para hiv
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
MXPA02006679A (es) Composicion farmaceutica.
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR9809425A (pt) Conjugados alfa interferon-polietilenoglicol para terapia de infecção
TW200733953A (en) Materials and methods for treating viral infections
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
BRPI0409711A (pt) tratamento ou prevenção de infecções respiratórias virais com peptìdeos da alfa timosina
CY1113277T1 (el) ΧΡΗΣΗ ΘΥΜΟΣΙΝΗΣ α1, ΜΟΝΗΣ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΡΤΧ3 Ή ΓΚΑΝΣΙΚΛΟΒΙΡΗ, ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΜΟΛΥΝΣΗΣ ΚΥΤΟΜΕΓΑΛΟΙΟΥ
PE20001386A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina-interferon alfa
WO2021202992A3 (en) Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19
BR9916893A (pt) Tratamento
BRPI0407140A (pt) Droga terapêutica para vìrus
BR0108997A (pt) Terapia imune adjuvante para hiv
DE60113304D1 (de) Verwendung von langem pentraxin ptx3 zur herstellung eines arzneimittels zur verhütung und heilung von autoimmunkrankheiten
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
BR9915644A (pt) Uso de compostos de 17-cetoesteróides e seus derivados, metabolitos e precursores no tratamento de vìrus de hepatite c e outros togavìrus
BR0311696A (pt) Tratamento de hepatite c na população asiática com interferon-beta subcutâneo
BRPI0511107A (pt) tratamento ou prevenção de infecções virais respiratórias com compostos imunomoduladores
BRPI0608326A2 (pt) suporte de exoesqueleto para colocação de uma fita de tratamento dental
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
AR029337A1 (es) Uso de interferon alfa pegilado para la preparacion de un medicamento para la terapia contra el hiv

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.